(Q36115429)

English

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

author name string

C J Lash

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

A E Li

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

M Rutland

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

B C Baguley

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

L J Zwi

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

W R Wilson

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

1 August 1998

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

78

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

439-445

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1998.512

0 references

Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

Bioreductive drugs for cancer therapy: the search for tumor specificity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

Flavone acetic acid--preclinical and clinical activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

Blood flow modification in the sccvii tumor: Effects of 5-Hydroxytryptamine, hydralazine, and propanolol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 October 2017

Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 July 2018

Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 July 2018

Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 July 2018

Therapeutic advantage of hypoxic cells in tumors: a theoretical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 July 2018

Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 July 2018

Hyper-responsiveness to 5-HT2Agonists by Tumour-linked Arterioles in Mice: Consequences for Tumour Growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 July 2018

Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

2 July 2018

Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

23 September 2018

Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

23 September 2018

Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063102

23 September 2018

A comparison of vascular-mediated tumor cell death by the necrotizing agents gr63178 and flavone acetic acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor-specific antigen(s) in a spontaneous mammary carcinoma of C3H mice. I. Quantitative cell transplants into mammary-tumor-agent-positive and -free mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunomodulatory actions of xanthenone anticancer agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Important role of serotonin in the antitumor effects of recombinant human tumor necrosis factor-alpha in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Flavone Acetic Acid on Lewis Lung Carcinoma: Evidence for an Indirect Effect1

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively ac

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the rate of clearance of xenon (133Xe) and pertechnetate ion (99mTcO4-) in murine tumors and normal leg muscles

1 reference

https://pubmed.ncbi.nlm.nih.gov/9716024

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1998.512

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36115429&oldid=1946806407"